Genetix Biotherapeutics operates as a biotechnology company that develops genetic therapies for patients with severe rare diseases. The company offers food and drug administration (FDA)-approved genetic therapies that aim to treat the underlying causes of sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy. It primarily serves the healthcare sector, focusing on patients and families affected by these rare genetic conditions. Genetix Biotherapeutics was formerly known as Bluebird Bio. It was founded in 1992 and is based in Somerville, Massachusetts.

Jounce Therapeutics specializes in cancer immunotherapy within the biotechnology sector. The company focuses on mobilizing the immune system to attack cancer by identifying targets and related biomarkers to tailor immunotherapies for individual patients. Jounce Therapeutics serves the healthcare and pharmaceutical sectors with its cancer treatment pipeline. It was founded in 2013 and is based in Cambridge, Massachusetts. In May 2023, Jounce Therapeutics was acquired by Concentra Biosciences at a valuation of $97.5M.

Tizona Therapeutics offers the development of immunotherapies for cancer treatment. It offers creating therapies that modulate the immune system to enhance the body's ability to combat cancer and to prevent the immune system from attacking healthy tissues in autoimmune diseases. It serves the healthcare and pharmaceutical sectors with its treatments for cancer and autoimmune diseases. It was founded in 2015 and is based in South San Francisco, California.

Incyte operates as a biopharmaceutical company involved in the discovery and development of medicines within the healthcare sector. The company focuses on a portfolio of marketed products and clinical candidates, particularly in Oncology and Inflammation, and Autoimmunity, aimed at addressing unmet medical needs. It was founded in 1991 and is based in Wilmington, Delaware.

Kite Pharma operates in cell therapy technology within the biotechnology sector, focusing on treating cancer. The company's main offerings include engineered T cell therapies designed to treat certain types of blood cancer by reengineering a patient's immune cells to target and attack cancer cells. It serves the healthcare sector, with a focus on providing cancer treatments. It was founded in 2009 and is based in Santa Monica, California. In October 2017, Kite Pharma was acquired by Gilead Sciences at a valuation of $11.9B.

Alaunos Therapeutics (NASDAQ: TCRT) is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of in-licensed cancer drugs to address unmet medical needs. The company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for patient treatment. Alaunos Therapeutics was formerly known as Alaunos Therapeutics. It was founded in 2003 and is based in Boston, Massachusetts.